The misery of motion sickness could be ended within five to ten years thanks to a new treatment being developed by scientists.

The cause of motion sickness is still a mystery but a popular theory among scientists says it is to do with confusing messages received by our brains from both our ears and eyes, when we are moving. It is a very common complaint and has the potential to affect all of us, meaning we get a bit queasy on boats or rollercoasters. However, around three in ten people experience hard-to-bear motion sickness symptoms, such as dizziness, severe nausea, cold sweats, and more.

Using an inexpensive drug for every hip or knee replacement since 2013 has helped St. Michael's Hospital reduce its number of red blood cell transfusions performed during these surgeries by more than 40 per cent without negatively affecting patients, according to new research.

The drug tranexamic acid, known as TXA, prevents excessive blood loss during surgeries.

TXA had been shown to be effective in orthopedic, trauma and cardiac patients but less than half of eligible patients at St. Michael's received this drug because of a previous province-wide shortage. The drug was given only to patients at high risk of requiring a blood transfusion.

It’s about time. The FDA is cracking down on the sale of a natural substance that most of us consume every day. It is the chemical caffeine, and it’s the “energy” in energy drinks. (This is a misnomer. They should be called “drinks that do nothing until a chemical stimulant is added.”)

Hospira has announced that Inflectra, (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). A biosimilar is a biologic medicine that has been developed to treat the same diseases as the originator product and the marketing hope is that it will deliver a 20-30 percent reduction in the price paid for the therapy.

"Carbonated drinks linked with out-of-hospital cardiac arrest of cardiac origin"

Right away, this looks suspicious. 

"Linked with" is a standard junk science term that translates roughly into: "Let's see if I can get some headlines by manipulating people into thinking that there is a nebulous relationship between something stupid, and their health, even though I know damn well that it isn't real."
A man goes into a butcher shop to buy some steak.

Man: "How much is your steak?"
Butcher: "$4.99 a pound."
Man:       "That's ridiculous! The butcher across town sells steak for $3.99 a pound!"
Butcher: "Then buy it from him."
Man:       "I tried, but he's all out."
Butcher:  "Well, when I'm out, I'll sell it for $1.99 per pound!"

Pretty good joke, but even better when it's applied to what's going on now with generic drug prices. That is, assuming you can figure it out.

But, one thing is clear: They are going up, and really fast.

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a new study in Tobacco Control which suggests that the primary effect of varenicline (marketed as Chantix) has only been to displace the use of older tobacco addiction therapies, such as nicotine patches and the antidepressant, bupropion (Zyban).

Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.

Seema Kumar, M.D., a pediatric endocrinologist in the Mayo Clinic Children's Center, has been studying the effects of vitamin D supplementation in children for 10 years, through four clinical trials and six published studies. To date, Dr. Kumar's team has found limited benefit from vitamin D supplements in adolescents. The latest study, Effect of Vitamin D3 Treatment on Endothelial Function in Obese Adolescents, appears online in Pediatric Obesity.

The FDA, following the advice of their advisory panel, voted yesterday to approve Addyi, aka "Female Viagra," or "Pink Viagra." Good move? Bad? Keep reading...

So, I get in a pissy mood once in a while. Before you judge, you try taking the Times Square-Grand Central Station shuttle every day. See what kind of mood you end up in:

Then I read something so infuriatingly stupid in the Huffington Post — which is of questionable value even on a good day — that my already-sour disposition headed even further south.